These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 11176801)

  • 21. Vermont to require drug makers to disclose payment to doctors.
    Petersen M
    N Y Times Web; 2002 Jun; ():C1, C12. PubMed ID: 12159894
    [No Abstract]   [Full Text] [Related]  

  • 22. Personal use of drug samples by physicians and office staff.
    Westfall JM; McCabe J; Nicholas RA
    JAMA; 1997 Jul; 278(2):141-3. PubMed ID: 9214530
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Marketing drugs: debating the real cost. Concern about close ties between doctors and pharmaceutical firms are prompting new financial disclosure laws and education efforts.
    Brand R
    State Legis; 2008 Sep; 34(8):26-9. PubMed ID: 18754159
    [No Abstract]   [Full Text] [Related]  

  • 24. Pharmaceutical industry interactions in family medicine residencies decreased between 2008 and 2013: a CERA study.
    Brown SR; Evans DV; Fugh-Berman A
    Fam Med; 2015 Apr; 47(4):279-82. PubMed ID: 25853598
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmaceuticals and medical devices: business practices.
    Steiner DJ
    Issue Brief Health Policy Track Serv; 2013 Dec; ():1-36. PubMed ID: 24482889
    [No Abstract]   [Full Text] [Related]  

  • 26. The ethics of pharmaceutical industry gift-giving: the role of a professional association.
    Morin K; Morse LJ
    Am J Bioeth; 2003; 3(3):54-5. PubMed ID: 14594494
    [No Abstract]   [Full Text] [Related]  

  • 27. [Effects of a mandatory guideline that prohibit hospital doctors from accepting any form of benefits in any form from the pharmaceutical industry].
    Gundermann C; Meier-Hellmann A; Bauer M; Hartmann M
    Dtsch Med Wochenschr; 2010 May; 135(3):67-70. PubMed ID: 20077378
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Are we providers or physicians?
    Baxter JD
    Arch Intern Med; 2009 Oct; 169(18):1725. PubMed ID: 19822834
    [No Abstract]   [Full Text] [Related]  

  • 29. Banning pens and pads misses the main point.
    Terry SF; Burke W
    Am J Bioeth; 2003; 3(3):63-5. PubMed ID: 14594500
    [No Abstract]   [Full Text] [Related]  

  • 30. The hidden persuaders: subtle advertising in radiation oncology.
    Hutchison P; Halperin EC
    Int J Radiat Oncol Biol Phys; 2002 Nov; 54(4):989-91. PubMed ID: 12419423
    [No Abstract]   [Full Text] [Related]  

  • 31. Conflicts of interest between physicians and the pharmaceutical industry and special interest groups.
    Schetky DH
    Child Adolesc Psychiatr Clin N Am; 2008 Jan; 17(1):113-25, ix-x. PubMed ID: 18036482
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Contact with pharmaceutical representatives: where does prudence lead?
    Appelbaum PS
    Am J Bioeth; 2010 Jan; 10(1):11-3. PubMed ID: 20077326
    [No Abstract]   [Full Text] [Related]  

  • 33. Industry-to-physician marketing and the cost of prescription drugs.
    Chiong W
    Am J Bioeth; 2003; 3(3):W28-W29. PubMed ID: 14594480
    [No Abstract]   [Full Text] [Related]  

  • 34. Marketing pharmaceutical products to physicians. Sales reps influence physicians' impressions of the industry.
    Creyer EH; Hrsistodoulakis I
    Mark Health Serv; 1998; 18(2):34-8. PubMed ID: 10180333
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Should dermatology residents accept educational support sponsored or funded by pharmaceutical companies?
    Lipoff JB; Grant-Kels JM
    J Am Acad Dermatol; 2013 May; 68(5):854-7. PubMed ID: 23602171
    [No Abstract]   [Full Text] [Related]  

  • 36. National survey on the attitudes of Canadian physicians towards drug-detailing by pharmaceutical representatives.
    Strang D; Gagnon M; Molloy W; Bedard M; Darzins P; Etchells E; Davidson W
    Ann R Coll Physicians Surg Can; 1996 Dec; 29(8):474-8. PubMed ID: 12380577
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Why self-regulation does not work: resolving prescription corruption caused by excessive gift-giving by pharmaceutical manufacturers.
    Mehta RS
    Food Drug Law J; 2008; 63(4):799-821. PubMed ID: 19593922
    [No Abstract]   [Full Text] [Related]  

  • 38. [Attitudes and behaviors of psychiatry residents and psychiatrists working in training institutes towards the relationship between the pharmaceutical industry and physicians].
    Gülöksüz S; Oral ET; Ulaş H
    Turk Psikiyatri Derg; 2009; 20(3):236-42. PubMed ID: 19757223
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Residents' perceptions over time of pharmaceutical industry interactions and gifts and the effect of an educational intervention.
    Schneider JA; Arora V; Kasza K; Van Harrison R; Humphrey H
    Acad Med; 2006 Jul; 81(7):595-602. PubMed ID: 16799279
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Refuse gifts, starting at university.
    Prescrire Int; 2011 Dec; 20(122):304. PubMed ID: 22232814
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.